Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Veradigm Inc. MDRX OTC

Other OTC • Healthcare • Medical - Healthcare Information Services • US • USD

SharesGrow Score
57/100
1/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$16.17
+260.1%

Veradigm Inc. (MDRX) is a Medical - Healthcare Information Services company in the Healthcare sector, currently trading at $4.49. It has a SharesGrow Score of 57/100, indicating a above average investment profile with 1 out of 7 criteria passed.

Analyst consensus target is MDRX = $16 (+260.1% upside).

Financials: revenue is $588M, -22.9%/yr average growth. Net income is $86M (loss), growing at +79.8%/yr. Net profit margin is -14.7% (negative). Gross margin is 52.5% (+17.3 pp trend).

Balance sheet: total debt is $219M against $1.0B equity (Debt-to-Equity (D/E) ratio 0.22, conservative). Current ratio is 2.95 (strong liquidity). Debt-to-assets is 14.6%. Total assets: $1.5B.

Analyst outlook: 16 / 43 analysts rate MDRX as buy (37%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 50/100 (Partial), Health 67/100 (Partial), Moat 64/100 (Partial), Future 52/100 (Partial), Income 10/100 (Fail).

$16.17
▲ 260.13% Upside
Average Price Target
Based on 43 Wall Street analysts offering 12-month price targets for Veradigm Inc., the average price target is $16.17, with a high forecast of $20.00, and a low forecast of $10.00.
Highest Price Target
$20.00
Average Price Target
$16.17
Lowest Price Target
$10.00

MDRX SharesGrow Score Overview

57/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 50/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 64/100
Gross margin is + market cap
FUTURE 52/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — MDRX

✓
VALUE Pass
100/100
MDRX trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $16, implying +256.3% from the current price $4. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
MDRX: -22.9%/yr revenue is, +79.8%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
~
PAST Partial
50/100
MDRX: 2 / 4 years profitable. weak. Score = 2 / 4 × 100. ≥ 80 = Pass.
View details →
~
HEALTH Partial
67/100
Balance sheet MDRX: Debt-to-Equity (D/E) ratio 0.22 (conservative), Current ratio is 2.95 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
64/100
MDRX: Gross margin is 52.5% (+17.3 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 64/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
52/100
Analyst outlook: 16 / 43 analysts rate MDRX as buy (37%). Analyst consensus target is $16 (+256.3% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
MDRX: Net profit margin is -14.7%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range3-6
Volume1.5K
Avg Volume (30D)266.1K
Market Cap$762.54M
Beta (1Y)0.56
Share Statistics
EPS (TTM)-0.67
Shares Outstanding$128.9M
IPO Date1999-07-26
Employees2,450
CEODonald D. Trigg
Financial Highlights & Ratios
Revenue (TTM)$588.02M
Gross Profit$308.42M
EBITDA$58.42M
Net Income$-86.46M
Operating Income$-27.1M
Total Cash$446.59M
Total Debt$219.44M
Net Debt$-227.15M
Total Assets$1.5B
Price / Earnings (P/E)-6.7
Price / Sales (P/S)1.3
Analyst Forecast
1Y Price Target$18.50
Target High$20.00
Target Low$10.00
Upside+312.0%
Rating ConsensusHold
Analysts Covering43
Buy 37% Hold 56% Sell 7%
Company Info
CountryUS
ExchangeOther OTC
CurrencyUSD
ISINUS01988P1084

Price Chart

Track all markets on TradingView
MDRX
Veradigm Inc. ↗  ·  Other OTC
Healthcare • Medical - Healthcare Information Services
3.00 52WK RANGE 6.00

People Also View

HQY
HQY
HealthEquity, Inc.
$81.36
+1.81%
 NXGN
NXGN
NextGen Healthcare, Inc.
$23.94
+0.13%
 AGTI
AGTI
Agiliti, Inc.
$10.05
-0.50%
 CERT
CERT
Certara, Inc.
$5.82
+0.52%
 HSTM
HSTM
HealthStream, Inc.
$20.34
-0.15%
 NRC
NRC
National Research Corporation
$17.04
+1.34%
 CPSI
CPSI
Computer Programs and Systems, Inc.
$9.19
+3.72%
 DH
DH
Definitive Healthcare Corp.
$1.01
+1.87%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message